The company has been active in deal-making, investing nearly $200 million (₹1,650 crore) in four acquisitions in the past two years - Sanzyme's probiotics portfolio, Novartis' heart failure drug Azmarda, pediatric brands from Dr Reddy's Laboratories and Razel (rosuvastatin) portfolio of Glenmark. The acquisitions boosted its annual revenue by ₹275 crore.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment